{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:33:07Z","timestamp":1790299987724,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010642","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000}}],"reference-count":62,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010642.pub2","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T18:44:02Z","timestamp":1470681842000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Endoscopic scoring indices for evaluation of disease activity in Crohn\u2019s disease"],"prefix":"10.1002","volume":"2016","author":[{"given":"Reena","family":"Khanna","sequence":"first","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Meibergdreef 9 - C2-112 Amsterdam Netherlands 1105 AZ"},{"name":"Robarts Clinical Trials; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; San Diego CA USA"},{"name":"University of California San Diego; Division of Gastroenterology; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GY","family":"Zou","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett G","family":"Levesque","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"10.1002\/14651858.CD010642.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S1873-9946(12)60402-4","article-title":"Endoscopy at three months from start of anti-TNF as a predictor for long-term endoscopic remission in Crohn's disease","volume":"6","author":"Af Bjorkesten","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5","key":"10.1002\/14651858.CD010642.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365521.2012.660542","article-title":"Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease","volume":"47","author":"Af Bjorkesten","year":"2012","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0003|cit3","first-page":"398","article-title":"Assessment and validation of endoscopic activity indices and their correlation to blood biochemical markers in Crohn's disease","volume":"27","author":"Bamba","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"A196","DOI":"10.1016\/S0016-5085(03)80985-X","article-title":"Endoscopic healing of Crohn's ileo-colitis with azathioprine","volume":"124","author":"Colombel","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010642.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD010642.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S1873-9946(12)60309-2","article-title":"Concordance in IBD endoscopic scoring requires expertise and training: preliminary results of an ongoing IG-IBD study","volume":"6","author":"Daperno","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0008|cit8","first-page":"S536","article-title":"Interobserver agreement in IBD endoscopic scoring: preliminary results of an ongoing IG-IBD study","volume":"142","author":"Daperno","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1590-8658(12)60216-3","article-title":"Interobserver agreement in IBD scores requires expertise and education: preliminary results from an ongoing IG-IBD study","volume":"44","author":"Daperno","year":"2012","journal-title":"Digestive and Liver Disease"},{"issue":"11","key":"10.1002\/14651858.CD010642.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.dld.2014.07.010","article-title":"Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD)","volume":"46","author":"Daperno","year":"2014","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1590-8658(14)60009-8","article-title":"Increasing interobserver agreement on IBD endoscopic scoring systems: results from the IGIBDEndo educational program","volume":"46","author":"Daperno","year":"2014","journal-title":"Digestive and Liver Disease"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0012|cit12","first-page":"S","article-title":"Increasing interobserver agreement on ibd endoscopic scoring systems: results from the IGIBDEndo educational program","volume":"146","author":"Daperno","year":"2014","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD010642.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ibd.20178","article-title":"Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level","volume":"13","author":"Denis","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0014|cit14","first-page":"S358","article-title":"Evolution of endoscopic activity scores under placebo therapy in Crohn's disease","volume":"138","author":"Ferrante","year":"2010","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0016|cit15","doi-asserted-by":"crossref","first-page":"S422","DOI":"10.1016\/S0016-5085(11)61734-4","article-title":"Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and\/or infliximab: a post-hoc analysis of the sonic data","volume":"140","author":"Ferrante","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010642.pub2-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","article-title":"Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC","volume":"145","author":"Ferrante","year":"2013","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/S0016-5085(11)61752-6","article-title":"Endoscopic score extracted from scope report correlates with Crohn's disease activity and CT enterography findings","volume":"140","author":"Green","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD010642.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/gutjnl-2012-302262","article-title":"Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol","volume":"62","author":"Hebuterne","year":"2013","journal-title":"Gut"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.14309\/00000434-201010001-01154","article-title":"Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: results of blinded central reading of recorded endoscopies from the MUSIC study","volume":"105","author":"Hebuterne","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD010642.pub2-BIB0020|cit20","first-page":"184","article-title":"Efficacy of anti-TNF-alpha agents in mucosal healing in Crohn disease","volume":"4","author":"Jalocha","year":"2009","journal-title":"Przeglad Gastroenterologiczny"},{"issue":"11","key":"10.1002\/14651858.CD010642.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.1097\/01.MIB.0000438736.06039.04","article-title":"Reliability of central readers in the evaluation of endoscopic disease activity in Crohn\u2019s disease","volume":"19","author":"Khanna","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1873-9946(14)60025-8","article-title":"Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease","volume":"8","author":"Khanna","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD010642.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/gutjnl-2014-308973","article-title":"Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease","volume":"65","author":"Khanna","year":"2016","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0025|cit25","first-page":"S","article-title":"Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's disease","volume":"146","author":"Khanna","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD010642.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.crohns.2013.05.005","article-title":"A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease","volume":"7","author":"Lobaton Ortega","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S1873-9946(12)60200-1","article-title":"A new rapid test for fecal calprotectin (FC) predicts mucosa healing in Crohn's disease (CD)","volume":"6","author":"Lobaton Ortega","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD010642.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD010642.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.crohns.2012.10.018","article-title":"Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD","volume":"7","author":"Molander","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0030|cit30","first-page":"S8","article-title":"Prediction of long-term clinical remission for adalimumab-treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES-CD","volume":"138","author":"Reinisch","year":"2010","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD010642.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ibd.21551","article-title":"Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity","volume":"17","author":"Rimola","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010642.pub2-BIB0032|cit32","first-page":"A618","article-title":"Infliximab maintenance treatment strategy results in mucosal healing in patients with Crohn's disease","volume":"122","author":"Rutgeerts","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD010642.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointestinal Endoscopy"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0034|cit34","first-page":"S85","article-title":"Early mucosal healing status predicts long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn's disease","volume":"138","author":"Rutgeerts","year":"2010","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0035|cit35","first-page":"S320","article-title":"Quality-of-life benefits for adalimumab-treated patients with moderate to severe Crohn's disease are predicted by early mucosal healing status","volume":"138","author":"Rutgeerts","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.gie.2015.06.018","article-title":"Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial","volume":"83","author":"Rutgeerts","year":"2016","journal-title":"Gastrointestinal Endoscopy"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10","key":"10.1002\/14651858.CD010642.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-2036.2008.03835.x","article-title":"Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings","volume":"28","author":"Sipponen","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD010642.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ibd.20490","article-title":"Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010642.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365520903483650","article-title":"Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment","volume":"45","author":"Sipponen","year":"2010","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD010642.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/1756-0500-2-221","article-title":"Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes","volume":"2","author":"Vieira","year":"2009","journal-title":"BMC Research Notes"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1873-9946(12)60153-6","article-title":"Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn\u2019s disease: a meta-study","volume":"6","author":"Bondjemah","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"3","key":"10.1002\/14651858.CD010642.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine Is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"10.1002\/14651858.CD010642.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/BF01296663","article-title":"Reproducibility of colonoscopic findings in Crohn's disease: A prospective multicenter study of interobserver variation","volume":"32","author":"Modigliani","year":"1987","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S674","DOI":"10.14309\/00000434-201210001-01667","article-title":"Certolizumab pegol plasma concentrations and endoscopic and clinical outcomes in Crohn's disease: a post hoc analysis of the MUSIC trial","volume":"107 Suppl 1","author":"Sandborn","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1873-9946(12)60006-3","article-title":"Development of three practical indices for mucosal healing among patients with moderate to severe Crohn\u2019s disease","volume":"6","author":"Sandborn","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1016\/S0016-5085(12)62064-2","article-title":"Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0050|cit50","first-page":"S39","article-title":"Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease","volume":"18","author":"Sandborn","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/S1873-9946(12)60422-X","article-title":"Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE","volume":"6","author":"Sandborn","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1097\/00054725-201212001-00091","article-title":"Adalimumab sustains deep remission for 3 years: data from CHARM and ADHERE","volume":"18","author":"Sandborn","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010642.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1016\/j.ejrad.2012.03.028","article-title":"Dynamic contrast-enhanced MRI in patients with luminal Crohn's disease","volume":"81","author":"Ziech","year":"2012","journal-title":"European Journal of Radiology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD010642.pub2-BIB0054|cit54","first-page":"S445","article-title":"Definitions of the endoscopic lesions in Crohn's disease: reproductibility study and GETAID expert consensus","volume":"148","author":"Buisson","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1093\/ecco-jcc\/jju027.317","article-title":"Definitions of the endoscopic lesions in Crohn's disease: reproductibility study and GETAID expert consensus","volume":"9","author":"Buisson","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD010642.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"142S","DOI":"10.1016\/S0197-2456(05)80019-4","article-title":"Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation","volume":"12","author":"Deyo","year":"1991","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010642.pub2-BIB0058|cit58","unstructured":"U.S. Food and Drug Administration (FDA) Workshop: Gastroenterology regulatory endpoints and the advancement of therapeutics (transcript) https:\/\/www.regulations.gov\/#!documentDetail;D=FDA-2013-N-0001-0130 (Accessed March 30, 2016)"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0021-9681(85)90005-0","article-title":"A methodological framework for assessing health indices","volume":"38","author":"Kirshner","year":"1985","journal-title":"Journal of Chronic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010642.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ibd.21355","article-title":"Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection","volume":"17","author":"Regueiro","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1002\/14651858.CD010642.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11136-004-0027-4","article-title":"Quantifying responsiveness of quality of life measures without an external criterion","volume":"14","author":"Zou","year":"2005","journal-title":"Quality of Life Research"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010642.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T01:57:22Z","timestamp":1717725442000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010642.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010642.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}